Pub Date : 2026-03-24DOI: 10.1016/j.endien.2026.501744
Maria Teresa Soriano Palao, Miriam Abellán Lucas, Juan José Ruiz Manzanera, Álvaro Cerezuela Fernández de Palencia, Beatriz Febrero Sánchez, José Manuel Rodríguez González
Solitary fibrous tumor (SFT) is a type of fibroblastic neoplasm with characteristic histological features, typically showing cytoplasmic expression of CD34 and nuclear expression of STAT6, associated with NAB2-STAT6 gene fusion. Thyroid localization is exceptionally rare, with only 51 cases reported worldwide to date. Its behavior in the thyroid is generally benign, although it may exhibit rapid growth, and its treatment is primarily surgical. The NAB2-STAT6 gene fusion, detected by immunohistochemistry, is pathognomonic for SFT. As exemplified in the present case, core needle biopsy (CNB) is more likely to provide sufficient material for microscopic, immunohistochemical, and other diagnostic techniques.
{"title":"Diagnosis and treatment of solitary fibrous tumors of the thyroid gland: the importance of an appropriate diagnostic approach.","authors":"Maria Teresa Soriano Palao, Miriam Abellán Lucas, Juan José Ruiz Manzanera, Álvaro Cerezuela Fernández de Palencia, Beatriz Febrero Sánchez, José Manuel Rodríguez González","doi":"10.1016/j.endien.2026.501744","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501744","url":null,"abstract":"<p><p>Solitary fibrous tumor (SFT) is a type of fibroblastic neoplasm with characteristic histological features, typically showing cytoplasmic expression of CD34 and nuclear expression of STAT6, associated with NAB2-STAT6 gene fusion. Thyroid localization is exceptionally rare, with only 51 cases reported worldwide to date. Its behavior in the thyroid is generally benign, although it may exhibit rapid growth, and its treatment is primarily surgical. The NAB2-STAT6 gene fusion, detected by immunohistochemistry, is pathognomonic for SFT. As exemplified in the present case, core needle biopsy (CNB) is more likely to provide sufficient material for microscopic, immunohistochemical, and other diagnostic techniques.</p>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501744"},"PeriodicalIF":1.8,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-10DOI: 10.1016/j.endien.2026.501731
Alba Barreiro Lusquiños, Ramiro Antonio Torrado Carrión, Carmen Blanco Barros
{"title":"HbA1c and hemoglobin \"La Desirade\" are they compatible for monitoring patients with diabetes? Contribution of a clinical case.","authors":"Alba Barreiro Lusquiños, Ramiro Antonio Torrado Carrión, Carmen Blanco Barros","doi":"10.1016/j.endien.2026.501731","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501731","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501731"},"PeriodicalIF":1.8,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-07DOI: 10.1016/j.endien.2026.501718
M Carmen Dameto Pons, Elena González Arnáiz, María Antequera González, María Casado Rodríguez, Diana García Sastre, María García Duque, Javier Castañón Alonso, Diana Ariadel Cobo, María D Ballesteros Pomar
Introduction: Malnutrition, sarcopenia and sarcopenic obesity have a significant impact on patients with heart failure. Therefore, it is important to perform nutritional assessment in this group of patients. The aim of this study is to determine the prevalence of malnutrition, sarcopenia and sarcopenic obesity in patients with heart failure, assess their quality of life, and eventually reassess their nutritional status.
Methodology: We conducted an observational study of patients with heart failure randomly referred by thecCardiology department and examined from 2021 through 2022 in the Nutrition department and then re-evaluated in 2024. The diagnosis of malnutrition was established using the GLIM criteria; sarcopenia was diagnosed according to EWGSOP2, and sarcopenic obesity according to the ESPEN/EASO criteria.
Results: A total of 41 patients were evaluated between 2021 and 2022, of whom 23 were re-evaluated in 2024. A total of 82.6% were men (mean age, 64 yeras [SD, 10.6]). Initially the prevalence of malnutrition was 21.7%; sarcopenia, 8.7%; and sarcopenic obesity, 4.3%. Caloric and protein requirements were not reached in 63.2% and 47.4%, respectively. A total of 26.1% of patients had a low calf circumference (CC) value; 100% had low lower limb strength, 90.9% had low gait speed, and 50% had low stability. All patients (100%) had a good quality of life as assessed by the MLHFQ questionnaire. At reassessment, the prevalence of malnutrition was 21.7%; sarcopenia, 17.4%; and sarcopenic obesity, 8.7%. Caloric and protein requirements were not reached in 60.9% and 78.3%, respectively. Furthermore, 52.2% had low CC value, 100% had low lower limb strength, 91.3% had low speed and 43.5% had low stability. A total of 91.3% had a good quality of life as assessed by the MLHFQ questionnaire.
Conclusions: Approximately 20% of patients with heart failure exhibit malnutrition at initial assessment and during follow-up. A high percentage of patients do not achieve nutritional requirements, presenting deterioration in functional tests and worsening quality of life. It is therefore advisable to establish early and sustained nutritional screening and assessment strategies in these patients, establishing the appropriate nutritional medical treatment.
{"title":"Prevalence of malnutrition, sarcopenia, and sarcopenic obesity in patients with heart failure.","authors":"M Carmen Dameto Pons, Elena González Arnáiz, María Antequera González, María Casado Rodríguez, Diana García Sastre, María García Duque, Javier Castañón Alonso, Diana Ariadel Cobo, María D Ballesteros Pomar","doi":"10.1016/j.endien.2026.501718","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501718","url":null,"abstract":"<p><strong>Introduction: </strong>Malnutrition, sarcopenia and sarcopenic obesity have a significant impact on patients with heart failure. Therefore, it is important to perform nutritional assessment in this group of patients. The aim of this study is to determine the prevalence of malnutrition, sarcopenia and sarcopenic obesity in patients with heart failure, assess their quality of life, and eventually reassess their nutritional status.</p><p><strong>Methodology: </strong>We conducted an observational study of patients with heart failure randomly referred by thecCardiology department and examined from 2021 through 2022 in the Nutrition department and then re-evaluated in 2024. The diagnosis of malnutrition was established using the GLIM criteria; sarcopenia was diagnosed according to EWGSOP2, and sarcopenic obesity according to the ESPEN/EASO criteria.</p><p><strong>Results: </strong>A total of 41 patients were evaluated between 2021 and 2022, of whom 23 were re-evaluated in 2024. A total of 82.6% were men (mean age, 64 yeras [SD, 10.6]). Initially the prevalence of malnutrition was 21.7%; sarcopenia, 8.7%; and sarcopenic obesity, 4.3%. Caloric and protein requirements were not reached in 63.2% and 47.4%, respectively. A total of 26.1% of patients had a low calf circumference (CC) value; 100% had low lower limb strength, 90.9% had low gait speed, and 50% had low stability. All patients (100%) had a good quality of life as assessed by the MLHFQ questionnaire. At reassessment, the prevalence of malnutrition was 21.7%; sarcopenia, 17.4%; and sarcopenic obesity, 8.7%. Caloric and protein requirements were not reached in 60.9% and 78.3%, respectively. Furthermore, 52.2% had low CC value, 100% had low lower limb strength, 91.3% had low speed and 43.5% had low stability. A total of 91.3% had a good quality of life as assessed by the MLHFQ questionnaire.</p><p><strong>Conclusions: </strong>Approximately 20% of patients with heart failure exhibit malnutrition at initial assessment and during follow-up. A high percentage of patients do not achieve nutritional requirements, presenting deterioration in functional tests and worsening quality of life. It is therefore advisable to establish early and sustained nutritional screening and assessment strategies in these patients, establishing the appropriate nutritional medical treatment.</p>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501718"},"PeriodicalIF":1.8,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-07DOI: 10.1016/j.endien.2026.501711
Cristina Tejera-Pérez
{"title":"Between benefit and risk: The role of dietary supplements in endocrinology.","authors":"Cristina Tejera-Pérez","doi":"10.1016/j.endien.2026.501711","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501711","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501711"},"PeriodicalIF":1.8,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-07DOI: 10.1016/j.endien.2026.501729
M Julia Ocón Bretón, Juan José Díez, Gabriel Olveira Fuster, Alberto Fernández Martínez, Alba Galdón Sanz-Pastor, Nuria Vilarrasa García, Beatriz Lardies Sánchez, Emma Anda Apiñaniz, Francisco Pita Gutiérrez, Manuel Gahete Ortiz, Juan José López Gómez, Rosa Casañ Fernández, Miguel Ángel Rubio Herrera, Náyade Del Prado, Javier Escalada San Martín, Francisco Javier Elola Somoza, Ignacio Bernabeu Morón
Objectives: RECALSEEN analyses the structure, activity and results of the Endocrinology and Nutrition Services and Units (S-U_EyN) of the Spanish National Health System (SNHS). This article presents data collected from the 2024 survey, as well as activity and outcome indicators from the SNHS Minimum Basic Data Set (CMBD) for 2007-2022.
Material and methods: Descriptive cross-sectional study of S-U_EyN in general acute care hospitals of the SNHS. Data obtained through an ad hoc survey referring to data from 2023 and discharges from S-U_EyN recorded in the CMBD (2022) were used.
Results: A total of 116 responses were obtained from S-U_EyN of 160 general acute care hospitals in the SNHS (72%). Fifty-six per cent of the S-U_EyN respondents were services or clinical management units. The average number of endocrinologists per S-U_EyN department was 8.4 (5.4), with an estimated rate of 2.9 endocrinologists per 100,000 inhabitants. In 74% of hospitals there is a Clinical Nutrition Unit (dependent on the S-U_EyN in 93% of cases) and 39% of S-U_EyNs have a day hospital. The portfolio of services offered by S-U_EyN is closely related to the complexity of the hospital. There is a significant trend to decline in hospitalisations for endocrine and nutritional diseases. Notable differences were found in resources, activity and outcomes between hospitals and autonomous communities. In relation to quality management and the implementation of good practices, there was still considerable room for improvement. The trend to worsening of short- and long-term complication indicators for diabetes mellitus in the period 2016-2022 should be analysed.
Conclusions: RECALSEEN provides relevant information on S-U_EyN and the evolution of endocrinology and nutrition care in the SNHS.
{"title":"RECALSEEN 2024. Resources and quality in the endocrinology and nutrition units of the National Health System of Spain.","authors":"M Julia Ocón Bretón, Juan José Díez, Gabriel Olveira Fuster, Alberto Fernández Martínez, Alba Galdón Sanz-Pastor, Nuria Vilarrasa García, Beatriz Lardies Sánchez, Emma Anda Apiñaniz, Francisco Pita Gutiérrez, Manuel Gahete Ortiz, Juan José López Gómez, Rosa Casañ Fernández, Miguel Ángel Rubio Herrera, Náyade Del Prado, Javier Escalada San Martín, Francisco Javier Elola Somoza, Ignacio Bernabeu Morón","doi":"10.1016/j.endien.2026.501729","DOIUrl":"https://doi.org/10.1016/j.endien.2026.501729","url":null,"abstract":"<p><strong>Objectives: </strong>RECALSEEN analyses the structure, activity and results of the Endocrinology and Nutrition Services and Units (S-U_EyN) of the Spanish National Health System (SNHS). This article presents data collected from the 2024 survey, as well as activity and outcome indicators from the SNHS Minimum Basic Data Set (CMBD) for 2007-2022.</p><p><strong>Material and methods: </strong>Descriptive cross-sectional study of S-U_EyN in general acute care hospitals of the SNHS. Data obtained through an ad hoc survey referring to data from 2023 and discharges from S-U_EyN recorded in the CMBD (2022) were used.</p><p><strong>Results: </strong>A total of 116 responses were obtained from S-U_EyN of 160 general acute care hospitals in the SNHS (72%). Fifty-six per cent of the S-U_EyN respondents were services or clinical management units. The average number of endocrinologists per S-U_EyN department was 8.4 (5.4), with an estimated rate of 2.9 endocrinologists per 100,000 inhabitants. In 74% of hospitals there is a Clinical Nutrition Unit (dependent on the S-U_EyN in 93% of cases) and 39% of S-U_EyNs have a day hospital. The portfolio of services offered by S-U_EyN is closely related to the complexity of the hospital. There is a significant trend to decline in hospitalisations for endocrine and nutritional diseases. Notable differences were found in resources, activity and outcomes between hospitals and autonomous communities. In relation to quality management and the implementation of good practices, there was still considerable room for improvement. The trend to worsening of short- and long-term complication indicators for diabetes mellitus in the period 2016-2022 should be analysed.</p><p><strong>Conclusions: </strong>RECALSEEN provides relevant information on S-U_EyN and the evolution of endocrinology and nutrition care in the SNHS.</p>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":" ","pages":"501729"},"PeriodicalIF":1.8,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-05DOI: 10.1016/j.endien.2026.501691
Josefa Rojas Villegas , Lourdes Garcia Garcia-Doncel , Maria Angeles Santos Mata , Yolanda Quirós López , Isabel Morón Rubio
{"title":"Study of the prevalence of obesity and sedentary lifestyle among school-aged children in the Health Area of Jerez, Northwest Coast and Sierra de Cádiz","authors":"Josefa Rojas Villegas , Lourdes Garcia Garcia-Doncel , Maria Angeles Santos Mata , Yolanda Quirós López , Isabel Morón Rubio","doi":"10.1016/j.endien.2026.501691","DOIUrl":"10.1016/j.endien.2026.501691","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 3","pages":"Article 501691"},"PeriodicalIF":1.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1016/j.endien.2026.501690
Carlos Ríos Gómez , Alicia Macías Batista , Ignacio García Puente , Laura Esther Guerrero Casanova , Miguel Carnero Gregorio
{"title":"Anaplastic thyroid cancer that responds to treatment with RET inhibitor","authors":"Carlos Ríos Gómez , Alicia Macías Batista , Ignacio García Puente , Laura Esther Guerrero Casanova , Miguel Carnero Gregorio","doi":"10.1016/j.endien.2026.501690","DOIUrl":"10.1016/j.endien.2026.501690","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 3","pages":"Article 501690"},"PeriodicalIF":1.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146120564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-07DOI: 10.1016/j.endien.2026.501686
Jorge Gabriel Ruiz-Sánchez , Alfonso Luis Calle-Pascual , Miguel Ángel Rubio-Herrera , María Paz De Miguel Novoa , Emilia Gómez-Hoyos , Isabelle Runkle
Background
The transtubular potassium gradient (TTKG) is a widely accepted tool for assessing mineralocorticoid activity in hyperkalemia. However, its clinical utility is often limited due to the unavailability of urine osmolality. Identifying alternative, more accessible urinary indices could improve diagnostic performance in suspected hypoaldosteronism.
Methods
We conducted a retrospective observational study including 106 hyperkalemic patients with hypoaldosteronism referred to Endocrinology Department. Through correlation analyses using Spearman's ρ and Pearson's r, we assessed the relationship between TTKG values and the urinary potassium-to-serum potassium ratio (UK+/SK+), the urinary potassium-to-creatinine ratio (UK+/creatinine), the fractional excretion of potassium (FEK), and the urinary sodium-to-potassium ratio (UNa+/UK).
Results
Mean age, 74 ± 12 years; mean TTKG, 3.8 ± 1.2, and UK+/creatinine, 62 ± 28 mmol/g. Median UNa+/UK+, 2.78 [1.81–3.72]; UK+/SK+, 5.1 [4–6.8]; FEK, 12.9% [7–18.9]. TTKG showed a strong positive correlation with UK+/SK+ (ρ = 0.706; p < 0.001) and FEK (ρ = 0.585; p < 0.001), and a moderate correlation with UK+/creatinine (r = 0.352; p = 0.011). An inverse strong correlation was observed with UNa+/UK+ (ρ = −0.655; p < 0.001).
Conclusions
UK+/SK, UK+/creatinine, FEK, and UNa+/UK+ seem to be practical alternatives for assessing renal potassium excretion in hyperkalemia associated with hypoaldosteronism. Further studies are warranted to validate these findings in larger and diverse cohorts.
{"title":"Beyond the transtubular potassium gradient: Alternative urinary markers for diagnosing hypoaldosteronism","authors":"Jorge Gabriel Ruiz-Sánchez , Alfonso Luis Calle-Pascual , Miguel Ángel Rubio-Herrera , María Paz De Miguel Novoa , Emilia Gómez-Hoyos , Isabelle Runkle","doi":"10.1016/j.endien.2026.501686","DOIUrl":"10.1016/j.endien.2026.501686","url":null,"abstract":"<div><h3>Background</h3><div>The transtubular potassium gradient (TTKG) is a widely accepted tool for assessing mineralocorticoid activity in hyperkalemia. However, its clinical utility is often limited due to the unavailability of urine osmolality. Identifying alternative, more accessible urinary indices could improve diagnostic performance in suspected hypoaldosteronism.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational study including 106 hyperkalemic patients with hypoaldosteronism referred to Endocrinology Department. Through correlation analyses using Spearman's <em>ρ</em> and Pearson's <em>r</em>, we assessed the relationship between TTKG values and the urinary potassium-to-serum potassium ratio (UK<sup>+</sup>/SK<sup>+</sup>), the urinary potassium-to-creatinine ratio (UK<sup>+</sup>/creatinine), the fractional excretion of potassium (FEK), and the urinary sodium-to-potassium ratio (UNa<sup>+</sup>/UK).</div></div><div><h3>Results</h3><div>Mean age, 74<!--> <!-->±<!--> <!-->12 years; mean TTKG, 3.8<!--> <!-->±<!--> <!-->1.2, and UK<sup>+</sup>/creatinine, 62<!--> <!-->±<!--> <!-->28<!--> <!-->mmol/g. Median UNa<sup>+</sup>/UK<sup>+</sup>, 2.78 [1.81–3.72]; UK<sup>+</sup>/SK<sup>+</sup>, 5.1 [4–6.8]; FEK, 12.9% [7–18.9]. TTKG showed a strong positive correlation with UK<sup>+</sup>/SK<sup>+</sup> (<em>ρ</em> <!-->=<!--> <!-->0.706; <em>p</em> <!--><<!--> <!-->0.001) and FEK (<em>ρ</em> <!-->=<!--> <!-->0.585; <em>p</em> <!--><<!--> <!-->0.001), and a moderate correlation with UK<sup>+</sup>/creatinine (<em>r</em> <!-->=<!--> <!-->0.352; <em>p</em> <!-->=<!--> <!-->0.011). An inverse strong correlation was observed with UNa<sup>+</sup>/UK<sup>+</sup> (<em>ρ</em> <!-->=<!--> <!-->−0.655; <em>p</em> <!--><<!--> <!-->0.001).</div></div><div><h3>Conclusions</h3><div>UK<sup>+</sup>/SK, UK<sup>+</sup>/creatinine, FEK, and UNa<sup>+</sup>/UK<sup>+</sup> seem to be practical alternatives for assessing renal potassium excretion in hyperkalemia associated with hypoaldosteronism. Further studies are warranted to validate these findings in larger and diverse cohorts.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 3","pages":"Article 501686"},"PeriodicalIF":1.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-05DOI: 10.1016/j.endien.2026.501688
Lucía Estévez Asensio , Esther Delgado García , Marina Gómez Andrés , María Samaniego Montoro , Antonia Maniega Rubio , Carmen Fernández Rodríguez , Ruth González Collantes , María José Bartolomé Albistegui , Marta Alonso Mesonero , Ana Belén Casas Marcos , Daniel A. de Luis Román , Emilia Gómez Hoyos
Introduction
Gender Affirming Hormone Therapy (GAHT) improves psychological well-being and certain quality-of-life parameters. Nevertheless, the satisfaction perceived by individuals undergoing this treatment remains unclear. The aim of this study was to assess such satisfaction using the Spanish adaptation of the received treatment satisfaction scale (CRES-4).
Material and methods
Cross-sectional observational study among transgender individuals who had been receiving GAHT for >1 year and had not undergone genital reassignment surgery. Participants were recruited from a Transgender Medicine Unit between January 2014 and January 2023. Demographic and clinical data were collected, along with responses to the CRES-4 scale. Statistical analysis performed using SPSS-V-23.
Results
Out of the 83 subjects included, 52 (62.7%) were identified as transgender men and 31 (37.3%) as transgender women. The median age at initiation of GAHT was 19 [17–25] years, with a median treatment duration of 3 [1.75–4] years at the time of evaluation. 95% of participants reported being satisfied with GAHT and 75% noted an improvement in the “perceived problem solution” domain. Emotional well-being improved markedly, with 68% reporting an acceptable emotional state after GAHT, compared to 9% before starting treatment. Satisfaction was not significantly associated with treatment duration, psychological comorbidity, age at initiation, non-genital gender-affirming surgeries or type of hormone therapy (feminizing vs. masculinizing).
Conclusions
Most transgender individuals reported high levels of satisfaction with GAHT when provided as part of comprehensive biopsychosocial care. The therapy improved emotional well-being and enhanced perceptions of problem resolution.
{"title":"Satisfaction associated with gender-affirming hormone therapy","authors":"Lucía Estévez Asensio , Esther Delgado García , Marina Gómez Andrés , María Samaniego Montoro , Antonia Maniega Rubio , Carmen Fernández Rodríguez , Ruth González Collantes , María José Bartolomé Albistegui , Marta Alonso Mesonero , Ana Belén Casas Marcos , Daniel A. de Luis Román , Emilia Gómez Hoyos","doi":"10.1016/j.endien.2026.501688","DOIUrl":"10.1016/j.endien.2026.501688","url":null,"abstract":"<div><h3>Introduction</h3><div>Gender Affirming Hormone Therapy (GAHT) improves psychological well-being and certain quality-of-life parameters. Nevertheless, the satisfaction perceived by individuals undergoing this treatment remains unclear. The aim of this study was to assess such satisfaction using the Spanish adaptation of the received treatment satisfaction scale (CRES-4).</div></div><div><h3>Material and methods</h3><div>Cross-sectional observational study among transgender individuals who had been receiving GAHT for >1 year and had not undergone genital reassignment surgery. Participants were recruited from a Transgender Medicine Unit between January 2014 and January 2023. Demographic and clinical data were collected, along with responses to the CRES-4 scale. Statistical analysis performed using SPSS-V-23.</div></div><div><h3>Results</h3><div>Out of the 83 subjects included, 52 (62.7%) were identified as transgender men and 31 (37.3%) as transgender women. The median age at initiation of GAHT was 19 [17–25] years, with a median treatment duration of 3 [1.75–4] years at the time of evaluation. 95% of participants reported being satisfied with GAHT and 75% noted an improvement in the “perceived problem solution” domain. Emotional well-being improved markedly, with 68% reporting an acceptable emotional state after GAHT, compared to 9% before starting treatment. Satisfaction was not significantly associated with treatment duration, psychological comorbidity, age at initiation, non-genital gender-affirming surgeries or type of hormone therapy (feminizing vs. masculinizing).</div></div><div><h3>Conclusions</h3><div>Most transgender individuals reported high levels of satisfaction with GAHT when provided as part of comprehensive biopsychosocial care. The therapy improved emotional well-being and enhanced perceptions of problem resolution.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 3","pages":"Article 501688"},"PeriodicalIF":1.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-07DOI: 10.1016/j.endien.2026.501779
Betina Biagetti
{"title":"Pituitary apoplexy: lessons from the Spanish registry for clinical stratification supported by advanced imaging","authors":"Betina Biagetti","doi":"10.1016/j.endien.2026.501779","DOIUrl":"10.1016/j.endien.2026.501779","url":null,"abstract":"","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 3","pages":"Article 501779"},"PeriodicalIF":1.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147391179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号